Back to discover
Disease

Proctitis

Late-stage therapeutic developmentEmerging research
MeSHProctitis
1
Publications
24
Clinical trials
3
Associated genes
2022
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones16View all 16
Results posted 1
Results expected 5
Recently completed 4
Other updates 5
+8 more in the activity timeline below
Activity timeline16

Clinical trials

13 sponsors · 2 new · 5 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Recruiting · AbbVie

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Recruiting · Hoffmann-La Roche

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Recruiting · Sanofi

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

Phase 3 · Recruiting · Takeda

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Active, not recruiting · Hoffmann-La Roche

A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy

Phase 3 · Active, not recruiting · AbbVie
Recruiting

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Recruiting · AbbVie

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Recruiting · Hoffmann-La Roche

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Recruiting · Sanofi

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

Phase 3 · Recruiting · Takeda
Recently completed

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis

Phase 3 · Completed · Alfasigma S.p.A.

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

Phase 4 · Completed · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis

Phase 3 · Completed · Eli Lilly and Company

A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of Risankizumab in Breast Milk of Lactating Women With Inflammatory Bowel Disease Who Are Receiving Risankizumab Therapeutically

Phase 4 · Completed · AbbVie

Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis

Phase 2/3 · Completed · Tanta University

A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab

Phase 3 · Completed · Eli Lilly and Company

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes7
  • HIV Infections1
  • Mpox, Monkeypox1
  • Proctitis1
  • Sexual and Gender Minorities1
  • Sexually Transmitted Diseases1
  • Smallpox1
  • Tonsillitis1
Leading journals1
  • Lancet (London, England)1
Leading researchers8
  • Acosta-Velásquez KS1
  • Agud-Dios M1
  • Alemany A1
  • Antón A1
  • Arando M1
  • Arroyo-Andrés J1
  • Cabrera JM1
  • Calderón-Lozano L1
Affiliations (unnormalised)6
  • Clinical Laboratory North Metropolitan Area1
  • Clinical Research Department1
  • Hospital Universitari Vall d'Hebron1
  • Hospital Universitario 12 de Octubre1
  • Hospital Universitario La Paz1
  • University Hospital Germans Trias i Pujol1

Associated genes

3 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CCR10.31OTUD30.21TMCO40.09

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).

Identifiers
MeSHProctitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.